ओरिस्कन् बायोटेक इन्डिया प्राइवेट लिमिटेड
( कंपनी
अधिनियम 1956 के अंतर्गत
स्थापित )
ORISCON BIOTECH (I) PVT LTD
Regd. Office : Plot No: C- 80, Ganesh Nagar,Pandav Nagar
Complex, New Delhi -110092,
Corporate Office:Plot No: C-31/32, G-3,
Ganesh Nagar, Pandav Nagar Complex, New Delhi -110092 ,
Phone No: 011- 22486954
Email
orisconbiotech@gmail.com
( Click here )
Oriscon'sVision
"We are a company registered under the
Indian Companies Act 1956 in the year 2006 at New Delhi . At Oriscon Biotech
india private limited Our philosophy is to provide economically priced good
quality Pharmaceutical Products to the humankind at large. We also believe that
there should be no compromise on the health of a human being. Our vision is to
become a significant major Pharmaceutical Company in INDIA by providing good
quality & affordable economical medicine for the treatment of all types of life threatening disease. "
Oriscon'sMission
"We
are still in the process of building our own fully integrated, commercial stage
bio pharmaceutical company that invents, develops and markets safe and
effective small molecule drugs to treat patients with debilitating and life -
threatening diseases primarily in cancer , tuberculosis and kala-azar &
inflammation . We intend to make & accomplish this through the following
innovative strategies:
“We
are meticulously making available pharmaceutical products , and constantly
improving existing product mix, thereby carving out a niche for ourselves in
the field of pharmaceutical marketing in INDIA. We shall provide total customer
satisfaction through excellent quality control along with most economically
priced Pharmaceutical Products”
Standard Quality policy of the
Company :
Your
company is dedicated to provide consistently High Quality range of Products in
the field of human Health care to the satisfaction of medical community and all
consumers at most economical price. This is being achieved by cumulative
efforts from the top to bottom by maintaining quality control aimed at Defect
prevention rather than Defect Detection".
Cost-effective Marketing strategy
:
Your
company's track record of development, particularly in the nick area of
improved cost-beneficial marketing strategy for latest various drugs molecules
is excellent. It also provides a wide variety of generic drugs along with a
range of sophisticatedly made drug formulations at most economical price.
All
of you must remember," Success depends on your ability to shape the future
by anticipating and responding to change. You should also know that you have
never been better positioned to achieve this".
==================================================================
Present Status: ORISCON BIOTECH (I) PVT LTD has been incorporated under
the Company's Act on 20th June 2006 having its Registered
& Corporate Office in New Delhi. Our business of different procurement
agencies since 2006 has been the base of our development, which empowered us to
start marketing of our Trade Mark Branded Pharmaceutical Products
from Feb 2011 with an investment of Rs. 2 Crores through field force.
<
Marketing through field force in Bihar & Jharkhand >
At present, we are marketing only 18
products on contract manufacturing (Third Party Basis) in Bihar & Jharkhand
through hard core Marketing Personnel, who are having strong potential to
generate optimum sales volume in the coming year.
Future Prospects: We
are still in the process of generating additional fund of US $ 2
million (Rs.10 Crores), which is the least amount needed to establish
our own Manufacturing Unit and also empowered us to be able to launch our Total
Registered Trade Mark’s Brand on all India basis. We can also use this fund for
strengthening and streamlining the present marketing position in the coming
year.
The Break-even point of manufacturing unit be achieved within
the very first operational year by procuring orders from other Marketing
Company besides making our own products.
After establishing our own
Manufacturing Unit, we can also be able to make available quality medicines at
economical price to the needy poor patients, who are unable to treat the life
threatening disease like Malaria, Kala-azar, Tuberculosis, Diabetes and other
ailments only because of their inability to purchase costly life saving
essential medicines, vaccines & other oral antibiotics. Our collective
efforts in this regard can generate an additional job opportunity to more
than 400 EDUCATED PERSONNEL
FUTURE SCOPE:
In the year
under review, our seventh consecutive financial result promise to explore the
possibility for establishment of a new manufacturing unit with own R&D
Laboratory at the costs of Rs.10 Cr. in Himachal Pradesh. We have in the process of finalising a
nodal agency.
WHEREAS
the company “Oriscon Biotech (I) Pvt Ltd” decided to finalised / purchase a
Pharmaceuticals Manufacturing Unit in the state of Himachal Pradesh at the cost
of Rs. Six Crores besides that the company also needs to infuse Further Rs. four
crores as a running capital, which is needed to run the factory.
BOARD of DIRECTORS of company has already authorised
Sri Priya Ranjan Shrivastava ( Chairman & Managing Director) to sell the
properties described herein “AS IS WHERE IS BASIS AND AS IS WHATEVER IS BASIS”
towards satisfaction of the of the company by inviting tenders/bids in a sealed
envelope from interested purchasers/bidders on the terms and conditions as mutually
decided upon.
|
DESCRIPTION AS ON THE
DATE OF 26Th FEBRUARY_2013
AS PER MARKET VALUE
|
|
RESIDENTIAL HOUSE
MEASURING (6000 SQ. FT.) CONSTRUCTED BUILDING AT MOTIHARI
DISTRICT IN PRIME LOCATION AT FOLLOWING :-
ADDRESS :- SHRI RAM BHAVAN, M/O:
PAITHAN PATTI, MAIN ROAD, PO: MOTIHARI ,
DIST: EAST CHAMPARAN,PIN
CODE : 845401, BIHAR (INDIA)
|
To
Whom It May Concern
Pl find below the Sale Notice of “SHRI RAM BHAVAN”
Prime Commercial Property located @ Main Road, Motihari, East Champaran for all
of your kind consideration to a noble cause:
PUBLIC NOTICE OF SALE
Sale Notice of Immovable properties mortgaged to
Oriscon Biotech (I) Pvt Ltd under as a collateral security by BOARD RESOLUTION
in this regard. The listed property of company’s Chairman & Managing
Director had been mortgaged by its Chairman & Managing Director by Board
Resolution to our own company “Oriscon Biotech (I) Pvt Ltd” as a
collateral security provided to company promoter’s investment on dated 20th May_2007,
under clause 6,7, 8 & 9 of the Mortgage Resolution there under.
Now we
have decided to sale the property for the purchase or establishing our own
Pharmaceutical Manufacturing Unit in the name of Oriscon Biotech (I) Pvt Ltd in
Himachal Pradesh, which guaranteed to achieve the BREAK-EVEN point within the
very 1st operational year, besides it will create further job
opportunity to more than 400 Educated Persons. The only reason to arrange the
required amount is our inability to arrange a loan either from Financial
Institutions of India & Abroad or from individual Venture capitalist around
the globe since last three years without any success. Now our company decided
to move forward without waiting for the things to be happened in favour of
company after exploring the all-possible options to get LOAN.
Whereas,
the company “ORISCON BIOTECH INDIA PRIVATE LIMITED” is the sole proprietor under the future mortgage
made in favour of company as a collateral security on behalf of BOARD of
DIRECTORS by its Chairman & Managing Director “MR. PRIYA RANJAN SHRIVASTAVA & SMT SHAIL DEVI”. (Bboth are
sole proprietor of the property listed below as a legal heir of Late Rameshwar
Nath shrivastava – The original registered dead holder of constructed house
“SHRI RAM BHAVAN” at District Motihari with absolute title & mutation right
since the year 1953).
FINANCIAL RESULTS:
While it is still early days of organisational development,
despite that your company is making solid progress.
DIVIDEND:
Your Directors
are happy to recommend a dividend of 14% (inclusive of dividend tax). The
right shares issued during the period April to March ( 2012 - 13 ) are also
qualify for full year's dividend. The Company's financial results for the
financial year ended 31st March 2013 are as summarised:
The present
Authorised share capital of the company is Rs.40,00,000/-(Rupees Forty Lacs
only) divided into 4,00,000 (Four Lacs) equity shares of Rs.10/- (Rupees Two
only) each. Your Board recommends that to enhance the Equity base for growth
and expansion plans of the Company.
The Authorised
Capital of the Company be increased from Rs.40,00,000/-(Rupees Forty Lacs only)
divided into 4,00,000 (Four Lacs) equity shares of Rs.10/- (Rupees Ten only)
each to Rs.2,00,00,000/-(Rupees Two crore only) divided into 20,00,000 (Twenty
Lacs) Equity shares of Rs.10/- (Rupees Ten only) each. It is therefore,
proposed to increase the authorized capital from Rs.40,00,000/-( Rupees Forty
Lacs only) to Rs.2,00,00,000/- (Rupees Two crore only) by creation of 16,00,000
(Sixteen Lacs) New equity shares of Rs.10/- (Rupees Ten only) each.
Consequently, Clause V of the Memorandum of Association and Article 3 (a) of
the Articles of Association of the Company has been altered.
A Copy of
Memorandum and Articles of Association of the Company together with the
proposed alteration will be made available for inspection by the Members of the
Company at its registered office between 11:00 a.m. and 1:00 p.m. on any
working day of the Company until the date of Annual General Meeting.
In terms of the
provisions of Section (s) 16, 31and 94 consent of the Members is required for
any alteration in Memorandum and Articles of Association of the Company. The
Board recommends the Resolutions for your approval.
Under section
293(1)(d) of the Companies Act, 1956, the Board of Directors cannot except with
the consent of the Company borrow moneys apart from temporary loans obtained
from the Company's bankers in the ordinary course of business in excess of the
aggregate of paid-up capital and free reserves of the Company, that is to say,
reserves not set apart for any specific purpose.
The members of
the Company at the Extra-ordinary General meeting held on April 20, 2012 authorised (Priya Ranjan Shrivastava –CMD) by Special
resolution of Board of Directors of the Company to borrow up to a limit of Rs.
2 crores. In view of increased volume of business envisaged in the forthcoming
months, it is proposed to continue the authorisation of the Board to Priya
Ranjan Shrivastava –CMD for borrowing
limit up to Rs2 crores and for this purpose approval under Section 293(1)(d) of
the Act is extended in next financial year.
Your Company is
dealing in Institutional supply of Pharmaceuticals Generic products with the
various procurement departments.
Every Company
has to concentrate on both fronts the present to continue its operation
successfully at the current level in the stronghold area for generating
operational profit ,and the future to prepare itself for the challenges lying
ahead. Since Bihar is considered a Gold Mine for Pharmaceutical Business due to
very high rate of consumption of medicine by per capita population. This is the
reason that all Pharma Companies have started their marketing venture from
Bihar. Therefore, this aspects of marketing is on our plus side ;
considering the facts that promoters of this company are having eighteen years
of Marketing Experience of each and every town of Bihar & Jharkhand. Our
company has set forth to achieving Rs.2 Crores sales in the year (2013-14) with
a team of 25 Medical Representatives, Two Zonal Sales Managers & Five
Regional Managers.
DIRECTORS:
One of the
director of the Company Mr. Abinash Chandra Verma are being disqualified on
charges of committing forgery & cheating.
Mr.Priya
Ranjan Shrivastava - as a Chairman & Managing Director, Mr.Kamlendra Kumar -
as a Joint Managing Director, Dr.Amaresh Kumar Singh - as a Director Human
Resources, Jugal Sah - as Investment Committee Director & Mr. Manoj Kumar
Thakur as a Legal Advisor of the Company. Dr. Bijay Kumar Gupta as Director
Product Research & Mr. Mithilesh Kumar as Director Welfare Committee.
Note:
a)
In case of Mr. Abinash Chandra Verma who was entrusted as
Director Audit Committee had misused his position by way of committing forgery
& cheating during his tenor at New Delhi.
He had also done Embezzlement of company’s cash kept in the office on different
occasions by using smart technique of falsifying the records by removing a
small amount of money and made false entry in the record the register to look
it technically correct. On several occasion in the past he was requested to
appear before enquiry committee at our corporate office in New Delhi & last
date was fixed on 28/06/2013 to attend along with Cash Register & Receipt
for the year (2011-12) but he is still avoiding to face the disciplinary
committee. The Board of Directors has authorised Mr. Priya Ranjan Shrivastava
(CMD) to deliver The Last Notice personally during stay at Motihari to Mr.
Abinash Chandra Verma & Company will initiate legal proceeding after
receiving status report on forgery & cheating done Mr. Abinash Chandra Verma.
b)
We are sorry to inform all
of you that two of our Esteemed Directors named Sri Uday Kant Thakur &
Sri Kunal Mishra are no more in this world, their sudden demise is
irreparable loss to our extended family of
the company and we all pay homage to the departed soul .
There is a
clear procedure for appointments to the Board. Such appointments are formal and
transparent and a matter for the Board as a whole. There is a clear division of
responsibility to ensure a balance of power, such that no one individual has
unfettered powers of decision-making. At 31 March 2013, the Board
comprised Non-Executive and Executive Directors who, with their
experience, knowledge and skill, add to the successful operation of the
Company.
Chairman and
Managing Director –
Managing the
Executive Committee is the responsibility of the whole time Director, Mr.
Priya Ranjan Shrivastava.
Shareholder
Representation :
Board:
Mr. Priya Ranjan
Shrivastava, Mr Kamlendra Kumar, Mr.Jugal Sah, Mr. Mithilesh Kumar, Dr. Bijay Kumar Gupta , Dr. Amaresh Kumar Singh
Audit
Committee:
Mr Tarun Kumar
(Advocate), although he is not a Board Member
Investment
Committee:
Mr. Jugal Sah
Remuneration
Committee:
Mr Tarun
Kumar , although he is not a Board Member.
Transformation
Committee:
Dr.Amaresh Kumar Singh, Mr. Manoj Kumar Thakur
RESTRUCTURING
MARKETING PROFILE:
However when a
new vendor is to be approved as the situations demand Oriscon Biotech Private
Limited has written down procedures as per law for approval of new vendors.
Stability study of the product and its quality is done when there is a change
in manufacturer / vendor / supplier of critical materials like active
ingredients of pharmaceutical molecule , Primary Packing materials & any
critical equipments.
All finished products are tested to the specified standards as per norms given in specification. All the products of our company are subjected to chemical and microbiological analysis for total counts of microbes and absence of pathogenic organisms. The products are released for dispatch after compliance of the products to the specified standards.
All finished products are tested to the specified standards as per norms given in specification. All the products of our company are subjected to chemical and microbiological analysis for total counts of microbes and absence of pathogenic organisms. The products are released for dispatch after compliance of the products to the specified standards.
PERSONNEL
None of the
employees of the Company is in receipt of remuneration drawing in excess
of limits prescribed under Section 217 (2A) of the Companies Act, 1956 read
with (Particulars of Employees) Rules, 1975 as amended and hence no information
is furnished thereto.
PROPOSED
CHANGE OF STATUS TO A PUBLIC LIMITED COMPANY IN NEAR FUTURE
The Board of
Directors has decided to take further steps to convert the same into a
Public Limited Company in near future.
INDUSTRIAL
RELATIONS
Cordial
industrial relations prevailed during the year.
DEPOSITS
Your Company
has not accepted any public deposit during the period under review.
AUDITORS
M/S JHA SHAILENDRA & ASSOCIATES., CHARTERED
ACCOUNTANTS, NEW DELHI , were appointed as first-auditors of the
Company and their term of office expires at the ensuing Annual General Meeting.
They, being eligible, offer themselves for appointment. A Certificate under
Section 224 (1B) of the Companies Act, 1956 has been obtained from them.
DIRECTORS'
RESPONSIBILITY STATEMENT
In terms of
Section 217(2AA) of the Companies Act, 1956, your directors confirm:
That in the
preparation of the annual accounts, the applicable accounting standards had
been followed:
that the
applicable accounting policies have been consistently followed and that they
had made judgments and estimates that are reasonable and prudent, so as to give
a true and fair view of the state of affairs of the Company at the end of the
financial year and of the profit of the Company for that period;
That they had
taken proper and sufficient care for the maintenance of adequate accounting
records, in accordance with the provisions of the Companies Act, 1956 for
safeguarding the assets of the Company and for preventing and detecting fraud
and other irregularities; and
That they had
prepared the annual accounts on a going concern basis.
INFORMATION
AS PER SECTION 217(1)(E) OF THE COMPANIES ACT, 1956
Your Company
has no activity relating to conservation of energy or technology absorption.
Your Company did not have any foreign exchange earnings or outgo during the
year.
TECHNOLOGY
ABSORPTION
Not Applicable
FOREIGN
EXCHANGE EARNINGS / OUTGO
The foreign
exchange earnings/outgo of the Company for the year under review was nil.
ACKNOWLEDGEMENT
The Directors
take this opportunity to express their appreciation for the cooperation
received from the State Government of New Delhi, the Company's Bankers,
valuable customers and others concerned with the Company.
Your Directors,
also thank the executives, staff and employees of the Company for their
valuable services and support during the year.
By Order of the
Board,
For Oriscon
Biotech (India) Private Limited
( Priya Ranja
Shrivastava )
Chairman & Managing
Director
